(Reuters) -On Monday, the U.S. Food and Drug Administration published a notice to the Federal Register ahead of a speech by President Donald Trump, approving a version of leucovorin made by GlaxoSmithKline that the company had previously withdrawn from the FDA’s consideration when it stopped manufacturing the drug. Read full story
Explainer-Why is leucovorin being considered as an autism treatment?
